• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Allergan opens new clinical research and development center in N.J.

Author(s):

Allergan has opened a new research and development center in Bridgewater, N.J.

Irvine, Calif. - Allergan has opened a new research and development center in Bridgewater, N.J.

The 93,000-square foot facility will focus on clinical development and is expected to eventually house several hundred employees, according to a company statement.

"We will continue to increase our investment in R&D to fuel innovation and expect to spend over $1 billion in 2013. Our New Jersey clinical development site will allow us to benefit from the expertise of the many talented R&D professionals that reside in this state and, most importantly, bring novel medical therapies to patients across the world,” said David E.I. Pyott, Allergan board chairman, president and CEO.

Allergan has headquarters in California, a presence in more than 100 countries and approximately 10,500 employees worldwide.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.